Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Randomized phase III ANGEL study of rivoceranib (apatinib) plus best supportive care (BSC) vs placebo plus BSC in patients with advanced/metastatic gastric cancer who failed >= 2 prior chemotherapy regimens
- Authors
- Kang, Y-K.; Kang, W. K.; Di Bartolomeo, M.; Chau, I.; Yoon, H. H.; Cascinu, S.; Ryu, M-H.; Kim, J. G.; Lee, K-W.; Oh, S. C.; Takashima, A.; Kryzhanivska, A.; Chao, Y.; Vladimirov, V.; Evesque, L.; Schenker, M.; McGinn, A.; Sankar, N.; Wyrwicz, L.; Boku, N.
- Issue Date
- 201910
- Conference Name
- ANNALS OF ONCOLOGY
- Place
- 영국
Barcelona, SPAIN
- Conference Name
- 44th Congress of the European-Society-for-Medical-Oncology (ESMO)
- ISSN
- 0923-7534
1569-8041
- Files in This Item
- There are no files associated with this item.
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Oh, Sang Cheul
- Guro Hospital (Department of Medical Oncology and Hematology, Guro Hospital)